Fidelity Investments
INMB icon

Fidelity Investments’s INmune Bio INMB Stock Holding History

Fidelity Investments’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.4K Sell
13,590
-507
-4% -$722 ﹤0.01% 4617
2025
Q4 		$22K Buy
14,097
+10,926
+345% +$19.5K ﹤0.01% 4422
2025
Q3 		$6.56K Buy
3,171
+661
+26% +$1.51K ﹤0.01% 4714
2025
Q2 		$5.8K Sell
2,510
-463
-16% -$3.4K ﹤0.01% 4678
2025
Q1 		$23.2K Buy
2,973
+1,344
+83% +$10.7K ﹤0.01% 4170
2024
Q4 		$7.61K Buy
1,629
+205
+14% +$1.07K ﹤0.01% 4548
2024
Q3 		$7.67K Buy
1,424
+1,339
+1,575% +$9.52K ﹤0.01% 4513
2024
Q2 		$750 Sell
85
-500
-85% -$4.93K ﹤0.01% 4827
2024
Q1 		$6.87K Buy
585
+500
+588% +$6.04K ﹤0.01% 4406
2023
Q4 		$957 Hold
85
– – ﹤0.01% 4754
2023
Q3 		$581 Hold
85
– – ﹤0.01% 4699
2023
Q2 		$772 Sell
85
-7
-8% -$56 ﹤0.01% 4752
2023
Q1 		$594 Buy
92
+83
+922% +$668 ﹤0.01% 4779
2022
Q4 		$57 Buy
+9
New +$64 ﹤0.01% 4928

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's INMB Position: Q1 2026 in Review

Fidelity Investments reduced its INmune Bio (INMB) stake by 3.6% in Q1 2026, selling an estimated $722 and leaving 13,590 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4617.

Fidelity Investments first reported a position in INMB in Q4 2022 and has held it in 14 quarters since. The position peaked at $23.2K in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Fidelity Investments held 13,590 shares of INmune Bio worth $15.4K as of Q1 2026.
  • Fidelity Investments sold 507 INmune Bio shares in Q1 2026, an estimated $722.
  • INmune Bio made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4617 holding.
  • Fidelity Investments first reported a position in INmune Bio in Q4 2022 and has held it in 14 quarters since.
  • Fidelity Investments's INmune Bio position peaked at $23.2K in Q1 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.